aTyr PharmaATYR
About: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Employees: 59
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
960% more call options, than puts
Call options by funds: $53K | Put options by funds: $5K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
17% more funds holding
Funds holding: 47 [Q2] → 55 (+8) [Q3]
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
6% more capital invested
Capital invested by funds: $79.8M [Q2] → $84.2M (+$4.44M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
10.94% less ownership
Funds ownership: 74.11% [Q2] → 63.17% (-10.94%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Joseph Pantginis 32% 1-year accuracy 124 / 389 met price target | 880%upside $35 | Buy Reiterated | 10 Dec 2024 |